“Amir Goldkorn, MD, of USC Norris Comprehensive Cancer Center, discusses findings from SWOG S1216, which showed that using circulating tumor cell (CTC) count at the start of treatment for metastatic castration-sensitive prostate cancer was prognostic of 7-month PSA response and progression-free survival at 2 years. He also discusses the possible challenges of integrating CTC count into standard practice.”
Originally from jnccn360.org
